IP Library › Granted Patent US 12,378,255
Granted Patent B2
US 12,378,255 · App. 18/484,588 · Granted Aug 5, 2025

Toll-like receptor antagonist compounds and methods of use

Inventors: Albert Frederick Candia, III (San Mateo, CA); Richard Thomas Beresis (San Francisco, CA); Robert L. Coffman (Portola Valley, CA)
Assignee: DYNAVAX TECHNOLOGIES CORPORATION
C07D487/04A61K45/06C07D231/56C07D235/18C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,378,255
App. No.
18/484,588
Granted
Aug 5, 2025
Kind
B2
Abstract

The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.

Claims (103)

1. A method of inhibiting the production of a cytokine in a subject in need thereof, comprising:

administering to the subject a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof:

wherein:

A 1 is C or N;

A 2 is CR 2 , N, or NR 2a ;

A 3 is CR 30 , N, or NR 3a ;

A 4 is N or CR 4 ;

A 5 is N or CR 5 ;

provided that two, three, or four of A 1 , A 2 , A 3 , A 4 , and A 5 are N; wherein the dashed lines indicate partial or delocalized bonds in an aromatic ring;

i and j are independently 0, 1, or 2;

R 1 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, or 3-12-membered heterocyclyl; wherein the C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclyl are independently optionally substituted by R 10A ;

each R 2 , R 3 , R 30 , R 4 , and R 5 is independently hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, or 3-12-membered heterocyclyl; wherein the C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclyl are independently optionally substituted by R 10A ;

each R 2a and R 3a is independently hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, or 3-12-membered heterocyclyl; wherein the C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10-membered heteroaryl, and 3-12-membered heterocyclyl are independently optionally substituted by R 10A ;

each R 6 , where present, is independently C 1 -C 6 alkyl optionally substituted by R 10A ;

n is 0, 1, 2, 3, or 4;

U is a bond or methylene optionally substituted by R 10 ;

V is a bond or C 1 -C 2 alkylene optionally substituted by R 10 ;

W is a bond or C 1 -C 4 alkylene optionally substituted by one or both of R W1 and R W2 ;

X is —CR X1 R X2 —;

Y is —CR Y1 R Y2 —;

R 7 is hydrogen, C 1 -C 6 alkyl, or taken together with R 8 to form an ethylene optionally substituted by R 10 , or taken together with R Y1 , R X1 , or R W1 , where present, to form a C 1 -C 6 alkylene optionally substituted by R 10 ;

R 8 is hydrogen, C 1 -C 6 alkyl optionally substituted by R 10 , C 6 -C 14 aryl, 5-10-membered heteroaryl, or taken together with R 7 to form an ethylene optionally substituted by R 10 , or taken together with R Y1 , R Y2 , R X1 , R X2 , or R W1 , where present, to form a C 1 -C 6 alkylene optionally substituted by R 10 , or taken together with R 10 , where present, to form a C 1 -C 6 alkylene, or taken together with R 9 and the nitrogen atom to which they are attached to form a 3-12-membered heterocyclyl optionally substituted by R 10 or a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R Y1 , R Y2 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R X1 , R X2 , R Y1 , R Y2 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X1 , R X2 , R Y1 , R Y2 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ;

R 9 is hydrogen, C 1 -C 6 alkyl optionally substituted by R 10 , or taken together with R 8 and the nitrogen atom to which they are attached to form a 3-12-membered heterocyclyl optionally substituted by R 10 or a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R Y1 , R Y2 , R 8 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R X1 , R X2 , R Y1 , R Y2 , R 8 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X1 , R X2 , R Y1 , R Y2 , R 8 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ;

R W1 , where present, is C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R 7 , R 8 , R X1 , or R Y1 to form a C 1 -C 6 alkylene optionally substituted by R 10 , or taken together with R W2 , R X1 , R X2 , R Y1 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ;

R W2 , where present, is C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R W1 , R X1 , R X2 , R Y1 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ;

R X1 is hydrogen, C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R 7 , R 8 , R Y1 , or R W1 , where present, to form a C 1 -C 6 alkylene optionally substituted by R 10 , or taken together with R X2 , R Y1 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X2 , R Y1 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ;

R X2 is hydrogen or C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R X1 , R Y1 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X1 , R Y1 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R 8 to form a C 1 -C 6 alkylene optionally substituted by R 10 ;

R Y1 is hydrogen, C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R 7 , R 8 , R X1 , or R W1 , where present, to form a C 1 -C 6 alkylene optionally substituted by R 10 , or taken together with R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R X1 , R X2 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X1 , R X2 , R Y2 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ;

R Y2 is hydrogen, C 1 -C 6 alkyl optionally substituted by R 10A , or taken together with R Y1 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R X1 , R X2 , R Y1 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R W1 , R W2 , where present, R X1 , R X2 , R Y1 , R 8 , R 9 and the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , or taken together with R 8 to form a C 1 -C 6 alkylene optionally substituted by R 10 ;

each R 10 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 3-12-membered heterocyclyl, 5-10-membered heteroaryl, C 6 -C 14 aryl, halogen, —CN, —OR 11 , —SR 11 , —NR 12 R 13 , —NO 2 , —C═NH(OR 11 ), —C(O) R 11 , —OC(O) R 11 , —C(O)OR 11 , —C(O) NR 12 R 13 , —NR 11 C(O) R 12 , —NR 11 C(O) OR 12 , —NR 11 C(O) NR 12 R 13 , —S(O) R 11 , —S(O) 2 R 11 , —NR 11 S(O) R 12 , —NR 11 S(O) 2 R 12 , —S(O) NR 12 R 13 , —S(O) 2 NR 12 R 13 , or —P(O) (OR 12 ) (OR 13 ); wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 3-12-membered heterocyclyl, 5-10-membered heteroaryl and C 6 -C 14 aryl of R 10 are independently optionally substituted by halogen, —CN, oxo, —OR 14 , —SR 14 , —NR 14 R 15 , —C(O) R 14 , —C(O) OR 14 , —S(O) R 14 , —S(O) 2 R 14 , —P(O) (OR 14 ) (OR 15 ), 3-12-membered heterocyclyl, 5-10-membered heteroaryl, C 6 -C 14 aryl, C 3 -C 8 cycloalkyl, or C 1 -C 6 alkyl optionally substituted by oxo, —OH or halogen, or taken together with R 8 to form a C 1 -C 6 alkylene;

each R 10A is independently oxo or R 10 ;

R 11 is independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl, or 3-6-membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl, and 3-6-membered heterocyclyl of R 11 are independently optionally substituted by halogen, oxo, —CN, —OR 16 , —NR 16 R 17 , —P(O) (OR 16 ) (OR 17 ), or C 1 -C 6 alkyl optionally substituted by halogen, —OH or oxo;

R 12 and R 13 are each independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl, or 3-6 membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl, and 3-6 membered heterocyclyl of R 12 and R 13 are independently optionally substituted by halogen, oxo, —CN, —OR 16 , —NR 16 R 17 or C 1 -C 6 alkyl optionally substituted by halogen, —OH or oxo;

or R 12 and R 13 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo, —OR 16 , —NR 16 R 17 , or C 1 -C 6 alkyl optionally substituted by halogen, oxo, or—OH;

R 14 and R 15 are each independently hydrogen, C 1 -C 6 alkyl optionally substituted by halogen or oxo, C 2 -C 6 alkenyl optionally substituted by halogen or oxo, or C 2 -C 6 alkynyl optionally substituted by halogen or oxo;

or R 14 and R 15 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo, or C 1 -C 6 alkyl optionally substituted by halogen or oxo; and

R 16 and R 17 are each independently hydrogen, C 1 -C 6 alkyl optionally substituted by halogen or oxo, C 2 -C 6 alkenyl optionally substituted by halogen or oxo, or C 2 -C 6 alkynyl optionally substituted by halogen or oxo;

or R 16 and R 17 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo, or C 1 -C 6 alkyl optionally substituted by oxo or halogen;

provided that when R 8 and R 9 are taken together with the nitrogen atom to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 , and the 5-10-membered heteroaryl is a fused ring heteroaryl comprising an aryl moiety fused to a heterocycle containing the nitrogen atom to which R 8 and R 9 are attached, the aryl moiety is not adjacent to the nitrogen atom to which R 8 and R 9 are attached.

2. The method of claim 1 , wherein at least one applies:

(a) A 1 is N, A 2 is CR 2 and A 3 is N;

(b) A 1 is C, A 2 is CR 2 or NR 2a and A 3 is NH;

(c) A 4 is N and A 5 is N;

(d) A 4 is N and A 5 is CR 5 ;

(e) A 4 is CR 4 and A 5 is CR 5 .

3. The method of claim 1 , wherein at least one applies:

(a) R 2a is C 1 -C 6 alkyl;

(b) R 4 is hydrogen;

(c) R 5 is hydrogen.

4. The method of claim 1 , wherein the compound is at least one of the following:

(a) the compound of formula (Ia):

(b) the compound of formula (II):

(c) the compound of formula (IIa):

(d) the compound of formula (III):

and

(e) the compound of formula (IIIa):

5. The method of claim 1 , wherein i is 2 and j is 1 or 2; or wherein i is 1 and j is 2; or wherein i is 1 and j is 1; or wherein i is 1 and j is 0; or wherein i is 0 and j is 0.

6. The method of claim 1 , wherein at least one applied:

(a) U is a bond;

(b) V is a bond;

(c) V is ethylene (—CH 2 CH 2 —).

7. The method of claim 1 , wherein: n is 0; or n is 1 or 2 and each R 6 is independently C 1 -C 6 alkyl optionally substituted by R 10A .

8. The method of claim 1 , wherein R 1 is phenyl optionally substituted by R 10A .

9. The method of claim 1 , wherein at least one applies:

(a) R 2 is C 1 -C 6 alkyl;

(b) R 3 is C 1 -C 6 alkyl;

(c) R 7 is hydrogen or C 1 -C 6 alkyl;

(d) W is a bond;

(e) W is C 1 -C 4 alkylene optionally substituted by one or both of R W1 and R W2 ;

(f) each of R X1 and R X2 is independently hydrogen or C 1 -C 6 alkyl;

(g) each of R Y1 and R Y2 is independently hydrogen or C 1 -C 6 alkyl;

(h) R 8 is hydrogen or C 1 -C 6 alkyl;

(i) R 9 is hydrogen or C 1 -C 6 alkyl optionally substituted by R 10 ;

(j) R 8 and R 9 are taken together with the nitrogen atom to which they are attached to form a 3-12-membered heterocyclyl optionally substituted by R 10 or a 5-10-membered heteroaryl optionally substituted by R 10 ;

(k) R Y1 , R Y2 , R 8 and R 9 are taken together with the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ;

(l) R X1 and R 8 are taken together to form a methylene (—CH 2 —);

(m) R Y1 and R 8 are taken together to form a propylene (—CH 2 CH 2 CH 2 —);

(n) R X1 , R X2 , R Y1 , R Y2 , R 8 , R 9 are taken together with the atoms to which they are attached to form a 5-10-membered heteroaryl optionally substituted by R 10 ;

(o) R 7 and R 8 are taken together to form an ethylene optionally substituted by R 10 .

10. The method of claim 1 , wherein the —N(R 7 )—W—X—Y—N(R 8 ) R 9 moiety is selected from the group consisting of:

11. The method of claim 1 , wherein the compound is at least one of:

(a) the compound of formula (IIa-1a-2):

(b) the compound of formula (IIa-1b-2):

(c) the compound of formula (IIa-1c-1):

(d) the compound of formula (IIa-1d-2):

(e) the compound of formula (IIa-1e-2):

(f) the compound of formula (IIa-1f-2):

(g) the compound of formula (VIII-a-2):

12. The method of claim 11 , or a salt or solvate thereof, wherein at least one applies:

(a) V is a bond;

(b) V is C 1 -C 2 alkylene;

(c) R 2 and R 3 are independently hydrogen or C 1 -C 6 alkyl;

(d) k is 1 or 2;

(e) n is 1 and R 6 is C 1 -C 6 alkyl;

(f) n is 0;

(g) R 8 and R 9 are independently C 1 -C 6 alkyl optionally substituted by R 10 ;

(h) R 8 and R 9 are taken together with the nitrogen atom to which they are attached to form a 3-12-membered heterocyclyl;

(i) R 10 is C 6 -C 14 aryl.

13. The method of claim 1 , wherein the cytokine is tumor necrosis factor-alpha.

14. The method of claim 1 , wherein the cytokine is interleukin-1 beta.

15. The method of claim 1 , wherein the cytokine is interleukin-6.

16. The method of claim 1 , wherein the cytokine is interferon-alpha.

17. The method of claim 1 , wherein the cytokine is selected from the group consisting of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interferon-alpha.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2024
From: CANDIA III, ALBERT FREDERICK; BERESIS, RICHARD THOMAS; COFFMAN, ROBERT L.
To: DYNAVAX TECHNOLOGIES CORPORATION
Reel/Frame 067379/0948 →
Continuity (5)
Continuation 17664305 · May 20, 2022
Continuation 16348816
Provisional Application 62421140 · Nov 11, 2016
Provisional Application 62421144 · Nov 11, 2016
Related Publication 20240182478A1 · Jun 6, 2024
References Cited (28)
US 8759305B2 · Barrat · 2014 [cited by applicant]
US 8853375B2 · Kandimalla · 2014 [cited by applicant]
US 9228184B2 · Guiducci · 2016 [cited by applicant]
US 11370794B2 · Candia, III · 2022 [cited by applicant]
US 11827641B2 · Candia, III · 2023 [cited by applicant]
US 20140221646A1 · Lipford · 2014 [cited by applicant]
US 20170174653A1 · Sherer · 2017 [cited by applicant]
US 20180037570A1 · Sherer · 2018 [cited by applicant]
US 20190270281A1 · Hirose · 2019 [cited by applicant]
US 20190345161A1 · Candia, III · 2019 [cited by applicant]
US 20220298162A1 · Candia · 2022 [cited by applicant]
JP 2013166770A · 2013 [cited by applicant]
WO 2011152485A1 · 2011 [cited by applicant]
WO 2012167046A1 · 2012 [cited by applicant]
Chemical Abstracts STN Registry Database, record for 894535-39-8, entered into STN on Jul. 19, 2006. 1 page. [cited by applicant]
Chemical Abstracts STN Registry Database, record for 894535-99-0, entered into STN on Jul. 19, 2006, 1 page. [cited by applicant]
Chemical Abstracts STN Registry Database, record for 894537-55-4, entered into STN on Jul. 19, 2006, 1 page. [cited by applicant]
Chemical Abstracts STN Registry Database, record for 894544-21-9, entered into STN on Jul. 19, 2006. 1 page. [cited by applicant]
Chemical Abstracts STN Registry Database, record for 894555-38-5, entered into STN on Jul. 19, 2006. 1 page. [cited by applicant]
Czarniecki, M. (Nov. 13, 2008, e-pub. Oct. 2, 2008). “Small Molecule Modulators of Toll-Like Receptors,” J. Med. Chem. 51(21):6621-6626. [cited by applicant]
Gosu, V. et al. (Nov. 14, 2012). “Therapeutic Applications of Nucleic Acids and Their Analogues in Toll-like Receptor Signaling,” Molecules 17:13503-13529. [cited by applicant]
Imberdis, T. et al. (Dec. 9, 2016). “Identification of Anti-Prion Compounds Using a Novel Cellular Assay,” J. Biol. Chem. 291(50):26164-26176. [cited by applicant]
International Preliminary Report on Patentability, issued on May 14, 2019, for PCT Application No. PCT/US2017/060946, filed on Nov. 9, 2017, 7 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Apr. 3, 2018, for PCT Application No. PCT/US2017/060946, filed on Nov. 9, 2017, 9 pages. [cited by applicant]
Kandimalla, E.R. et al. (Apr. 1, 2013, e-pub. Feb. 8, 2013). “Design, Synthesis and Biological Evaluation of Novel Antagonist Compounds of Toll-Like Receptors 7, 8 and 9,” Nucleic Acids Res. 41(6):3947-3961. [cited by applicant]
National Center for Biotechnology Information. PubChem Substance Record for SID 34321357, Deposit Date Dec. 5, 2007, 5 pages. [cited by applicant]
National Center for Biotechnology Information. PubChem Substance Record for SID 34321364, Deposit Date Dec. 5, 2007, 5 pages. [cited by applicant]
Patra; M.C. et al. (2016). “Recent Progress in the Development of Toll-Like Receptor (TLR) Antagonists,” Expert Opinion on Therapeutic Patents 26(6):719-730. [cited by applicant]